Drug eluting ophthalmic lenses - MediPrint Ophthalmic
Alternative Names: LL-A1; LL-C1; LL-D1Latest Information Update: 28 Apr 2025
At a glance
- Originator MediPrint Ophthalmics
- Class Antiallergics; Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cataracts
- No development reported Dry eyes; Hypersensitivity
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in Allergy in USA (Ophthalmic)
- 28 Apr 2025 No recent reports of development identified for preclinical development in Dry-eyes in USA (Ophthalmic)
- 24 Nov 2023 Preclinical trials in Cataracts in USA (Ophthalmic) prior to November 2023 (MediPrint Ophthalmic pipeline, November 2023)